Published in Atherosclerosis on December 01, 1993
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet (1998) 1.94
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Physical activity, nutrition, and dyslipidemia in middle-aged women. Iran J Public Health (2011) 1.52
Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation (2009) 1.51
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A (1995) 1.17
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest (1997) 1.14
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest (1996) 1.08
Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci (2012) 1.07
Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol (2005) 1.00
Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS One (2009) 0.96
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk? Vasc Health Risk Manag (2008) 0.92
Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry (2000) 0.92
Maternal and fetal genetic associations of PTGER3 and PON1 with preterm birth. PLoS One (2010) 0.91
Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol (2009) 0.91
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol (2007) 0.91
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol (2008) 0.90
Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur J Epidemiol (2010) 0.90
Validation of reported physical activity for cholesterol control using two different physical activity instruments. Vasc Health Risk Manag (2009) 0.90
Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem J (1996) 0.89
Paraoxonase 1 gene polymorphisms influence clinical features of open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol (2006) 0.89
Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environ Int (2013) 0.88
Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res (2012) 0.88
Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids (2012) 0.87
HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc (2014) 0.87
Hormonal and chemical regulation of paraoxonases in mice. J Pharmacol Exp Ther (2012) 0.86
The effect of grape seed extracts on serum paraoxonase activities in streptozotocin-induced diabetic rats. J Med Food (2010) 0.85
Dynamic variation in allele-specific gene expression of Paraoxonase-1 in murine and human tissues. Hum Mol Genet (2008) 0.85
Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol (2015) 0.84
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene (2015) 0.83
Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res (2012) 0.83
Effects of intronic and exonic polymorphisms of paraoxonase 1 (PON1) gene on serum PON1 activity in a Korean population. J Korean Med Sci (2011) 0.83
The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart Vessels (2007) 0.83
Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis (2010) 0.83
Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med (2008) 0.83
Evaluation of polymorphisms in paraoxonase 2 (PON2) gene and their association with cardiovascular-renal disease risk in Mexican Americans. Kidney Blood Press Res (2009) 0.82
Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Proc Natl Acad Sci U S A (2005) 0.82
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab (2013) 0.82
Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem J (2003) 0.81
Effect of vitamin e and selenium supplement on paraoxonase-1 activity, oxidized low density lipoprotein and antioxidant defense in diabetic rats. Bioimpacts (2011) 0.81
Total serum oxidant/antioxidant status and arylesterase activity in recurrent aphthous stomatitis. Ann Dermatol (2013) 0.81
PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. J Lipid Res (2015) 0.81
Paraoxonase: Its antiatherogenic role in chronic renal failure. Indian J Nephrol (2010) 0.80
Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res (2011) 0.80
PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. PPAR Res (2012) 0.79
Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. Br J Clin Pharmacol (2009) 0.79
Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis (2013) 0.79
Paraoxonase-1 (PON1) rs662 Polymorphism and Its Association with Serum Lipid Levels and Longevity in the Bama Zhuang Population. Med Sci Monit (2016) 0.79
Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids Health Dis (2003) 0.78
Increased Levels of Human Carotid Lesion Linoleic Acid Hydroperoxide in Symptomatic and Asymptomatic Patients Is Inversely Correlated with Serum HDL and Paraoxonase 1 Activity. J Lipids (2012) 0.78
Genistein as a potential inducer of the anti-atherogenic enzyme paraoxonase-1: studies in cultured hepatocytes in vitro and in rat liver in vivo. J Cell Mol Med (2012) 0.78
Antioxidant properties of HDL. Front Pharmacol (2015) 0.78
Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease. Dig Dis Sci (2007) 0.78
Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods. J Ocul Biol Dis Infor (2011) 0.78
Protective effect of paraoxonase 1 gene variant L55M in retinal vein occlusion. Mol Vis (2013) 0.77
Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutr Metab (Lond) (2014) 0.77
Paraoxonase 1 (PON1) C/T-108 association with longitudinal mean arterial blood pressure. Am J Hypertens (2012) 0.77
Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem J (1999) 0.77
Paraoxonase-1 55 LL Genotype Is Associated with No ST-Elevation Myocardial Infarction and with High Levels of Myoglobin. J Lipids (2012) 0.77
Atherothrombosis in South asians: implications of atherosclerotic and inflammatory markers. Open Cardiovasc Med J (2010) 0.77
Aerobic training modulates the effects of exercise-induced oxidative stress on PON1 activity: a preliminary study. ScientificWorldJournal (2014) 0.77
Serum paraoxonase activity and lipid hydroperoxide levels in adult football players after three days football tournament. Afr Health Sci (2013) 0.76
Paraoxonase1, its Q192R polymorphism and HDL-cholesterol in relation to intensive cardiac care unit stay in ischemic heart disease. Indian J Hum Genet (2014) 0.76
Time-dependent modulation of rat serum paraoxonase 1 activity by fasting. Pflugers Arch (2006) 0.76
Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. Oxid Med Cell Longev (2016) 0.76
Active Site Hydrophobicity and the Convergent Evolution of Paraoxonase Activity in Structurally Divergent Enzymes: The Case of Serum Paraoxonase 1. J Am Chem Soc (2016) 0.75
Concentration of Smaller High-Density Lipoprotein Particle (HDL-P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc (2016) 0.75
Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals. Dis Markers (2014) 0.75
Paraoxonase and arylesterase activities in dipper and non-dipper prehypertensive subjects. Medicine (Baltimore) (2015) 0.75
Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes. BMJ Open Diabetes Res Care (2016) 0.75
Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection. J Int AIDS Soc (2014) 0.75
Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.75
Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol. Korean Circ J (2016) 0.75
Differentially expressed serum proteins associated with calcium regulation and hypocalcemia in dairy cows. Asian-Australas J Anim Sci (2016) 0.75
Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA. J Lipid Res (2016) 0.75
Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. Am J Cardiovasc Dis (2012) 0.75
A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity. Curr Chem Genomics (2008) 0.75
Paraoxonase 2 protein is spatially expressed in the human placenta and selectively reduced in labour. PLoS One (2014) 0.75
Changes in the Serum Level of High Density Lipoprotein-cholesterol after Smoking Cessation among Adult Men. Korean J Fam Med (2012) 0.75
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Mol Cell Proteomics (2015) 0.75
Immunohistochemical analysis of paraoxonases and chemokines in arteries of patients with peripheral artery disease. Int J Mol Sci (2015) 0.75
Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World J Gastroenterol (2015) 0.75
Increased presence of oxidized low-density lipoprotein in the left ventricular blood of subjects with cardiovascular disease. Physiol Rep (2016) 0.75
Lipid peroxidation and paraoxonase-1 activity in celiac disease. J Lipids (2012) 0.75
Lower paraoxonase 1 activity in Tunisian bipolar I patients. Ann Gen Psychiatry (2010) 0.75
Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders. Nutrients (2017) 0.75
Paraoxonase (PON1) activity in patients with subclinical thoracic aortic atherosclerosis. Int J Cardiovasc Imaging (2014) 0.75
Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin (2017) 0.75
Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environ Int (2017) 0.75
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet (1999) 2.37
Cardiac stun in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg (1991) 2.13
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest (2002) 1.52
Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet (2000) 1.50
HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis (1995) 1.48
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome (1999) 1.44
Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet (1988) 1.42
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
What will increase the number of organs for transplantation? Some strategies to consider. CMAJ (1994) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis (1990) 1.32
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Effect of pectin on serum lipids and lipoproteins, whole-gut transit-time, and stool weight. Lancet (1976) 1.12
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol (2000) 1.08
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
The reticulocalbin gene maps to the WAGR region in human and to the Small eye Harwell deletion in mouse. Genomics (1997) 1.05
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest (2000) 1.03
Report and abstracts of the First International Workshop on Chromosome 9. Held at Girton College Cambridge, UK, 22-24 March, 1992. Ann Hum Genet (1992) 1.01
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Frequency of citation and outcome of cholesterol lowering trials. BMJ (1992) 0.98
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) (2000) 0.98
Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract (2003) 0.98
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors. Eur J Biochem (1995) 0.95
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet (1999) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2008) 0.94
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. Nat Nanotechnol (2011) 0.94
Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. Ann Rheum Dis (2005) 0.94
Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun (2000) 0.93
Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis (2004) 0.93
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2005) 0.93
Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest (2000) 0.92
The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure. Can J Cardiol (2001) 0.92
Disruption of the LF-A1 and LF-B1 binding sites in the human alpha-1-antitrypsin gene has a differential effect during development in transgenic mice. EMBO J (1991) 0.91
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med (2002) 0.90
Paraoxonase and coronary heart disease. Curr Opin Lipidol (1998) 0.90
Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr (1994) 0.90
Recurrent perianastomotic ileo/jejuno-colic ulceration. J Pediatr Gastroenterol Nutr (2000) 0.90
The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol (2002) 0.90
A comparison of methods for the immunoassay of serum apolipoprotein B in man. Clin Chim Acta (1976) 0.89
Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis (1992) 0.89